Top Story Today
The FDA Is Watching Clinical Trials in Real Time Now. Everything Changes.
The FDA launched a pilot with Amgen and AstraZeneca that gives regulators continuous, cloud-based access to clinical trial data as patients enroll, not months after trials end. Both pilots focus on oncology (mantle cell lymphoma and small cell lung cancer) and use a platform that automatically flags predefined safety and efficacy signals in days rather than months. If it scales, the downstream math is staggering: years potentially shaved off the typical decade-long path from discovery to approval.
Why it matters: This transforms the FDA from a distant gatekeeper into a real-time collaborator, potentially reshaping how every clinical trial in every therapeutic area operates for decades to come.
Read more →Deals & M&A
Bayer Drops $2.45 Billion on an Eye Implant That Reverses Glaucoma
Bayer is buying Perfuse Therapeutics for up to $2.45 billion to get PER-001, a six-month eye implant that showed something unheard of in trials: 37.5% of glaucoma patients actually regained vision while zero control patients improved. The deal is structured conservatively ($300M upfront) as Bayer scrambles to replace its Eylea franchise before biosimilars devour it.
Read more →Madrigal Pays Up to $1 Billion to Silence a Gene and Dominate MASH
Madrigal licensed Arrowhead's gene-silencing drug ARO-PNPLA3 for up to $1 billion, planning to combine it with its blockbuster Rezdiffra (approaching $1B in annual sales). The target: a genetic mutation that makes liver disease worse in a significant subset of MASH patients. It's the third major deal in a year as Madrigal builds a combination therapy empire.
Read more →GSK Bets $1 Billion on an RNA Drug That Melts Fat, Not Muscle
GSK licensed SiranBio's Phase 1 RNA drug SA030 for $55 million upfront (up to $1 billion total), targeting a protein called ALK7 that controls fat storage. The pitch: reduce belly fat while preserving lean muscle, solving GLP-1 drugs' biggest complaint. It's GSK's third major oligonucleotide deal in months as the company builds an entire RNA pipeline through licensing.
Read more →Geopolitics & Supply Chain
China Just Made It Illegal to Diversify Away From Chinese Pharma Manufacturing
China's Decree No. 834 took effect with zero warning, giving Beijing authority to punish any foreign company that switches suppliers, exits partnerships, or reduces sourcing from Chinese manufacturers. With China supplying the majority of global antibiotics and sole-sourcing key starting materials for nearly 41% of U.S. drug APIs, Western pharma now faces contradictory legal demands from Washington and Beijing simultaneously.
Read more →Company Moves
BioNTech Cuts 1,860 Jobs and Shuts Four Plants in Its Biggest Post-COVID Reckoning
BioNTech is closing manufacturing sites in Marburg, Idar-Oberstein, Tübingen, and Singapore, eliminating 1,860 jobs as revenue collapsed from €17.3 billion (2022) to a 2026 guide of €2.0-2.3 billion. The company is redirecting everything toward oncology, with 15 Phase III cancer trials planned by year-end and €17.2 billion in cash to fund the pivot.
Read more →Novo Nordisk Shelves Its Single-Chamber CagriSema Pen Exploration (and That's Actually Good News)
Novo dropped its exploratory single-chamber pen formulation for CagriSema, its next-gen obesity combo drug, but the launch timeline hasn't budged. The dual-chamber version (needed because the two drugs require incompatible pH levels) is the one with all the Phase 3 data and is the design submitted for regulatory approval, so ditching the alternative removes risk without costing a single day on the regulatory calendar.
Read more →CellCentric Raises $220M for a Single Epigenetic Cancer Pill
Investors including Fidelity, RA Capital, and Pfizer piled into an oversubscribed $220M round for CellCentric's oral myeloma drug inobrodib. Phase 2 data showed 60% response rates in patients who'd already failed cutting-edge immunotherapies; roughly double historical comparisons. The funding gives the Cambridge spin-out runway through pivotal readouts in 2027 without needing a partner.
Read more →